HomeCompareLVTX vs SPHD

LVTX vs SPHD: Dividend Comparison 2026

LVTX yields 114.94% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVTX wins by $7.02M in total portfolio value
10 years
LVTX
LVTX
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full LVTX calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — LVTX vs SPHD

📍 LVTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVTXSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVTX + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVTX pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVTX
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, LVTX beats the other by $2,208,801.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVTX + SPHD for your $10,000?

LVTX: 50%SPHD: 50%
100% SPHD50/50100% LVTX
Portfolio after 10yr
$3.54M
Annual income
$1,299,866.42/yr
Blended yield
36.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LVTX right now

LVTX
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$3.75
+115.5% upside vs current
Range: $1.50 — $6.00
Altman Z
-4.7
Piotroski
1/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVTX buys
0
SPHD buys
0
No recent congressional trades found for LVTX or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVTXSPHD
Forward yield114.94%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7.05M$26.5K
Annual income after 10y$2,599,161.52$571.32
Total dividends collected$6.38M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LVTX vs SPHD ($10,000, DRIP)

YearLVTX PortfolioLVTX Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$22,194$11,494.25$11,133$432.85+$11.1KLVTX
2$47,590$23,841.72$12,363$450.36+$35.2KLVTX
3$98,699$47,777.67$13,695$467.39+$85.0KLVTX
4$198,214$92,606.18$15,138$483.90+$183.1KLVTX
5$385,900$173,811.71$16,697$499.88+$369.2KLVTX
6$729,168$316,254.64$18,382$515.31+$710.8KLVTX
7$1,338,687$558,477.43$20,198$530.17+$1.32MLVTX
8$2,390,633$958,237.97$22,157$544.46+$2.37MLVTX
9$4,157,254$1,599,276.16$24,266$558.18+$4.13MLVTX
10$7,047,423$2,599,161.52$26,536$571.32+$7.02MLVTX

LVTX vs SPHD: Complete Analysis 2026

LVTXStock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Full LVTX Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this LVTX vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVTX vs SCHDLVTX vs JEPILVTX vs OLVTX vs KOLVTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.